Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study.

"Declarations Ethics approval and consent to participateThis study was approved by Gustave Roussy institutional review board (CSET N° 2023-234). Informed consent was obtained from all the patients. Results of genetic testing, when performed, were recorded. Genetic testing relied on Next Generation Sequencing of blood samples, acquired from blood biopsies during the NCT04932525 trial, and Informed consent was obtained from all the patients. In detail, this retrospective study complies with the French MR004 methodology regarding general data protection regulation for non-interventional retrospective health research (Délibération n° 2018-155 du 3 mai 2018) and received approval from our institutional review board (CSET N° 2023-234), in compliance with the Helsinki declaration. Patients were informed about their data use and those who declined access to their medical file were excluded from the study. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work did not benefit from a specific funding."